Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05995964 · ClinicalTrials.gov registry record · Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT05995964 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Pfizer. The registered enrollment target is 340 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05995964, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied. PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage. The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective. Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-07275315
- DRUG PF-07264660
Study Locations (20)
California
- Marvel Clinical Research - Huntington Beach
- California Allergy and Asthma Medical Group - Los Angeles
- University Dermatology Trials, INC. - Newport Beach
- Northridge Clinical Trials - Northridge
- Profound Research LLC - Oceanside
- Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc. - San Diego
- West Dermatology La Jolla - San Diego
- Sunwise Clinical Research - Walnut Creek
Florida
- Renaissance Research and Medical Group - Cape Coral
- Florida International Medical Research - Coral Gables
- Revival Research - Doral
- St. Jude Clinical Research - Doral
- SouthCoast Research Center - Miami
- Floridian Research Institute Llc - Miami
Arizona
- Onyx Clinical Research - Peoria - Peoria
- Medical Dermatology Specialists - Phoenix
- Onyx Clinical Research - Phoenix
- Banner - University Medicine Dermatology Clinic - Tucson
Alabama
- Allervie Clinical Research - Birmingham
Colorado
- AboutSkin Research, LLC - Greenwood Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2023-08-22 |
| Est. Completion | 2027-03-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05995964
The ClinicalTrials.gov registry entry for NCT05995964 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (44% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05995964 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05995964 about?
NCT05995964 is a clinical study titled "A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis". The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more....
What is the current status of trial NCT05995964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2023-08-22. Estimated completion is 2027-03-08.
What conditions does trial NCT05995964 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05995964?
The interventions under investigation include: Placebo (OTHER), PF-07275315 (DRUG), PF-07264660 (DRUG).
Who is sponsoring clinical trial NCT05995964?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05995964 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.